Marks M, Bell LCK, Jones I, Rampling T, Kranzer K, Morris-Jones S, Logan S, Pollara G. Clinical and Economic Impact of Implementing
OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clin Infect Dis 2021;
71:207-210. [PMID:
31603189 PMCID:
PMC7312207 DOI:
10.1093/cid/ciz991]
[Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 10/03/2019] [Indexed: 12/17/2022] Open
Abstract
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569–2594) per patient.
Collapse